Filament Health, through its parent company Rhelion Life Sciences, will supply its patented psilocybin drug candidate PEX010 to the University Health Network's PSI-PARK clinical trial. This randomized study evaluates psilocybin's effectiveness in treating depression in Parkinson's disease patients, a condition poorly managed by existing treatments. The trial, led by Dr. Joshua Rosenblat, aims to address a significant unmet medical need and build on promising early research showing psilocybin's potential benefits. Filament Health's standardized, pharmaceutical-grade PEX010 supports over 80 global research programs, highlighting its role in advancing psychedelic medicine.
Industrial Alliance Securities lowered Abeona Therapeutics' price target from $20 to $15 following a 14% stock drop after the company reported Q2 revenues of $11.4 million, missing analyst expectations. The company faces operational challenges with i...
Inovio Pharmaceuticals is progressing its DNA medicine pipeline with its lead candidate INO-3107 for Recurrent Respiratory Papillomatosis under FDA accelerated review, targeting a decision by October 30, 2026. The company raised $18.3 million in fund...
Morin Brit, a director at Life360, sold 15,582 shares of the company, generating $1 million from the transaction. This sale may indicate a personal financial decision or portfolio adjustment by the director. Investors might watch for any further insi...
AbCellera Biologics announced positive Phase 2 trial results for its experimental menopause drug ABCL635, which significantly reduced hot flash frequency by 83%. The stock surged 33.19% to a 52-week high of $11.32, boosting the company's market cap t...
TOMI Environmental Solutions reported a 118% year-over-year revenue increase to $2.25 million, surpassing analyst estimates of $1.84 million. The company also beat EPS expectations with a loss of $0.05 per share, better than the anticipated loss of $...
